Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mebendox is an oral **small-molecule anthelmintic** product marketed by Indo-Bangla Pharmaceuticals for the treatment of **helminth infections** such as threadworm, whipworm, roundworm, and hookworm infection. Its active ingredient is **mebendazole**, a benzimidazole antiparasitic that binds parasite **beta-tubulin** and inhibits microtubule polymerization, disrupting glucose uptake and other essential cellular functions in susceptible worms, which leads to parasite death or immobilization. In the provided context, Mebendox is described as an approved, marketed generic product in Bangladesh and is available as a 100 mg chewable tablet, with oral suspension also listed separately in company product information.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mebendox.